GYNOCARE Update: Modern Strategies to Improve Diagnosis and Treatment of Rare Gynecologic Tumors—Current Challenges and Future Directions

Riccardo Di Di Fiore, Sherif Suleiman, Bridget Ellul, Sharon A. O’toole, Charles Savona-ventura, Ana Felix, Valerio Napolioni, Neil T. Conlon, Ayse Elif Erson-bensan, Ilker Kahramanoglu, Miriam J. Azzopardi, Miriam Dalmas, Neville Calleja, Mark R. Brincat, Yves Muscat-baron, Maja Sabol, Vera Dimitrievska, Angel Yordanov, Mariela Vasileva-slaveva, Kristelle Von Von BrockdorffRachel A. Micallef, Paul Kubelac, Patriciu Achimas-cadariu, Catalin Vlad, Olga Tzortzatou, Robert Poka, Antonio Giordano, Alex Felice, Nicholas Reed, C. Simon Herrington, David Faraggi, Jean Calleja-agius

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

More than 50% of all gynecologic tumors can be classified as rare (defined as an incidence of ≤6 per 100,000 women) and usually have a poor prognosis owing to delayed diagnosis and
treatment. In contrast to almost all other common solid tumors, the treatment of rare gynecologic
tumors (RGT) is often based on retrospective studies, expert opinion, or extrapolation from other
tumor sites with similar histology, leading to difficulty in developing guidelines for clinical practice.
Currently, gynecologic cancer research, due to distinct scientific and technological challenges, is
lagging behind. Moreover, the overall efforts for addressing these challenges are fragmented across
different European countries and indeed, worldwide. The GYNOCARE, COST Action CA18117
(European Network for Gynecological Rare Cancer Research) programme aims to address these
challenges by creating a unique network between key stakeholders covering distinct domains from
concept to cure: basic research on RGT, biobanking, bridging with industry, and setting up the legal
and regulatory requirements for international innovative clinical trials. On this basis, members of
this COST Action, (Working Group 1, “Basic and Translational Research on Rare Gynecological
Cancer”) have decided to focus their future efforts on the development of new approaches to
improve the diagnosis and treatment of RGT. Here, we provide a brief overview of the current stateof-
the-art and describe the goals of this COST Action and its future challenges with the aim to
stimulate discussion and promote synergy across scientists engaged in the fight against this rare
cancer worldwide.
Original languageEnglish
Pages (from-to)493
JournalCancers
Volume13
Issue number3
DOIs
Publication statusPublished - 27 Jan 2021

Keywords / Materials (for Non-textual outputs)

  • rare gynecologic tumors
  • irculating tumor-specific markers
  • cancer stem cells
  • theranostics
  • biobanking
  • personalized medicine

Fingerprint

Dive into the research topics of 'GYNOCARE Update: Modern Strategies to Improve Diagnosis and Treatment of Rare Gynecologic Tumors—Current Challenges and Future Directions'. Together they form a unique fingerprint.

Cite this